EDE approves first nasal epinephrine spray

First nasal adrenaline spray

EURneffy is the first nasal adrenaline spray designed for the emergency treatment of severe allergic reactions in both adults and children aged four years and above, with dosage determined according to body weight.

A breakthrough in treatment delivery

Developed by ALK Abelló, the product represents a major advancement in the UAE’s healthcare sector by allowing epinephrine to be administered through the nose instead of injections.

Faster response in emergencies

This nasal delivery method enables quicker intervention during life-threatening allergic reactions, where rapid administration of epinephrine is essential. It also overcomes common challenges linked to injectable treatments, such as fear of needles and difficulty in use during emergencies.

Ease of use and accessibility

EURneffy is designed for simple and rapid use, allowing even non-medically trained individuals to administer it immediately. Its user-friendly design helps reduce hesitation and improves response time, ultimately enhancing patient safety and survival rates.

Accelerating access in the UAE

The Emirates Drug Establishment was introduced to this innovation during a recent visit to Denmark and collaborated closely with the manufacturer to fast-track its availability in the UAE, aiming to improve patient safety and quality of life.

Strengthening healthcare readiness

The approval forms part of EDE’s broader strategy to enhance healthcare preparedness and expand access to innovative treatments, aligning with global best practices and evolving patient needs in emergency care.

Official statement

Fatima Al Kaabi, Director General of the Emirates Drug Establishment, stated that the approval reflects the UAE’s commitment to accelerating the adoption of innovative therapies that directly impact patients’ lives. She emphasised the importance of accessible and easy-to-use treatments in critical situations to improve response rates and reduce risks.

Regulatory excellence

Al Kaabi added that approving the region’s first nasal adrenaline spray highlights the flexibility and efficiency of the UAE’s regulatory system in attracting and endorsing advanced medical solutions, thereby enhancing healthcare quality and emergency readiness.

Continued commitment to innovation

She affirmed that EDE will continue facilitating access to the latest treatments through advanced regulatory processes that ensure both speed and accuracy, supporting the availability of safe and effective therapies while promoting healthcare sustainability.

Industry perspective

Ghassan Al Qatib, Regional General Manager at ALK Abelló, described the approval as a significant step toward improving access to effective and user-friendly emergency treatments for patients and healthcare providers.

Ongoing collaboration

Al Qatib reaffirmed the company’s commitment to delivering innovative therapies in partnership with EDE, reflecting a shared goal of advancing pharmaceutical care in the UAE and across the region.

UAE as a hub for medical innovation

With this approval, the UAE strengthens its position as a leading centre for medical innovation, supported by a flexible regulatory framework that ensures rapid access to advanced treatments while maintaining the highest standards of quality and safety, ultimately improving public health and quality of life.